Forte Biosciences (FBRX) Competitors

Forte Biosciences (NASDAQ:FBRX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Which has better valuation & earnings, FBRX or LEXX?

Lexaria Bioscience has higher revenue and earnings than Forte Biosciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$31.48M	-$16.29	-0.83
Lexaria Bioscience	$230K	151.32	-$6.66M	-$0.44	-5.00

Is FBRX or LEXX more profitable?

Lexaria Bioscience's return on equity of -88.39% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-151.43%	-118.92%
Lexaria Bioscience	N/A	-88.39%	-84.05%

Do insiders & institutionals have more ownership in FBRX or LEXX?

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 9.6% of Forte Biosciences shares are owned by insiders. Comparatively, 7.6% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate FBRX or LEXX?

Forte Biosciences currently has a consensus price target of $23.58, suggesting a potential upside of 74.05%. Lexaria Bioscience has a consensus price target of $11.00, suggesting a potential upside of 400.00%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lexaria Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, FBRX or LEXX?

Forte Biosciences has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Does the media refer more to FBRX or LEXX?

In the previous week, Forte Biosciences had 12 more articles in the media than Lexaria Bioscience. MarketBeat recorded 12 mentions for Forte Biosciences and 0 mentions for Lexaria Bioscience. Forte Biosciences' average media sentiment score of 0.94 beat Lexaria Bioscience's score of 0.31 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Positive
Lexaria Bioscience	Neutral

Does the MarketBeat Community prefer FBRX or LEXX?

Forte Biosciences received 24 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 59.57% of users gave Forte Biosciences an outperform vote.

Company	Underperform	Outperform
Forte Biosciences	Outperform Votes 28 59.57%	Underperform Votes 19 40.43%
Lexaria Bioscience	Outperform Votes 4 100.00%	Underperform Votes No Votes

Summary

Lexaria Bioscience beats Forte Biosciences on 8 of the 15 factors compared between the two stocks.